证券代码：300108 证券简称：*ST 吉药 公告编号：2025-080 吉药控股集团股份有限公司 关于公司诉讼进展的公告 本公司及其董事会全体成员保证公告内容真实、准确、完整，公告不存 在虚假记载、误导性陈述或重大遗漏。 吉药控股集团股份有限公司（以下简称"公司"或"吉药控股"）于近日收到辽 宁省大连市中级人民法院下发的《执行通知书》案号：（2025）辽 02 执恢 166 号文件、吉林省磐石市人民法院下发的《民事起诉状》、《传票》（2025）吉 0284 民初 1305 号、（2025）吉 0284 民初 1306 号文件。现将具体情况说明如下： 一、本次新增诉讼的基本情况 基本情况：公司下属公司吉林金宝医药营销有限公司（以下简称"金宝医药"） 于 2021 年 12 月 8 日召开了第四届董事会第五十四次会议决议的公告（公告编号： 2021-074）、2021 年 12 月 24 日召开 2021 年第三次临时股东大会决议公告（公 告编号：2021-083）审议通过了《关于公司为孙公司吉林金宝医药营销有限公司 提供担保的议案》，为满足公司下属公司金宝医药日常经营和业务发展资金需要， 金宝医药拟向吉林磐 ...

Group 1 - Since May, several companies including *ST Zhongcheng, *ST Renle, *ST Hengli, and *ST Gongzhi have announced receipt of termination of listing advance notice, indicating a trend of companies leaving the capital market [1][3] - As of May 12, 2025, a total of 10 companies have received termination of listing advance notices from the Shanghai and Shenzhen Stock Exchanges, with additional companies like *ST Puli and *ST Xulan also facing similar fates [1][3] - The new delisting regulations have been implemented, leading to the first annual report season under these rules, resulting in multiple companies being warned of delisting risks and several directly delisted [5] Group 2 - *ST Renle reported a net asset of -387 million yuan for 2023 and -404 million yuan for 2024, triggering termination of listing due to financial report issues [3] - *ST Hengli's 2023 net profit was negative, and its revenue was below 100 million yuan, leading to a delisting risk warning [3][4] - *ST Zhongcheng's 2023 net asset was also negative, and its 2024 financial report received a qualified opinion, resulting in a proposed termination of listing [3][4] Group 3 - A total of 9 companies have completed delisting in 2025, with reasons ranging from continuous low stock prices to major violations [6][7] - The companies that have delisted include *ST Meixun, Haitong Securities, and *ST Boxin, among others, with various reasons for their delisting [7][8] - The trend indicates a significant number of companies facing financial difficulties and regulatory challenges, leading to increased scrutiny and potential delisting [10] Group 4 - The Beijing Stock Exchange may see its first delisted company, with Guandao Digital and Yun Chuang Data facing delisting risks due to audit issues [9][10] - Both companies have received audit opinions that could lead to termination of listing if they continue to meet financial delisting criteria in 2025 [10] - A total of 96 companies in the A-share market have been warned of delisting risks due to various financial issues, indicating a broader trend of financial instability among listed companies [10]

Core Viewpoint - Multiple *ST companies are facing delisting risks as they have received pre-delisting notices from the exchange due to various financial and trading indicators [2][5][6] Group 1: Financial Indicators and Delisting Notices - As of May 11, six *ST companies have received pre-delisting notices, with five touching financial delisting indicators and one touching trading delisting indicators [2] - The new delisting regulations have introduced stricter conditions for *ST companies to remove delisting risk warnings, requiring internal control audit reports to be unqualified; otherwise, delisting will occur [2][3] - *ST Zhongcheng, *ST Renle, and *ST Gongzhi received negative internal control audit opinions for their 2024 financial reports, indicating significant financial distress [3][5] Group 2: Specific Company Cases - *ST Zhongcheng announced on May 7 that it received a pre-delisting notice due to a negative net asset value for 2023 and a negative internal control audit opinion for 2024 [3][4] - *ST Renle received a pre-delisting notice on May 6, with a reported net asset of -387 million yuan for 2023 and -404 million yuan for 2024, along with negative audit opinions [5] - *ST Gongzhi also received a pre-delisting notice due to negative audit opinions for its financial reports [5] Group 3: Additional Delisting Factors - *ST Longjin is set to exit the A-share market due to negative profit and revenue figures, having received a pre-delisting notice on April 25 [6] - *ST Hengli faced delisting risks for failing to disclose its 2024 annual report on time, with a reported negative net profit and revenue below 100 million yuan [7] - *ST Jiyuan triggered the delisting indicator by having its stock price below 1 yuan for 20 consecutive trading days, leading to a pre-delisting notice [9]

Summary of Key Points Core Viewpoint - The A-share market shows a significant number of low-priced stocks, with 63 stocks priced below 2 yuan, indicating a potential area for investment analysis and opportunities in the market [1]. Group 1: Market Overview - As of May 6, the Shanghai Composite Index closed at 3316.11 points, with an average A-share price of 11.34 yuan [1]. - The distribution of high-priced and low-priced stocks is relatively small in the overall A-share market [1]. Group 2: Low-Priced Stocks - Among the 63 stocks priced below 2 yuan, the lowest is *ST Jiayao at 0.21 yuan, followed by *ST Pengbo at 0.62 yuan and Puli Tui at 0.69 yuan [1]. - 41.27% of the low-priced stocks are ST stocks, indicating a significant presence of companies under special treatment [1]. Group 3: Performance of Low-Priced Stocks - Out of the low-priced stocks, 49 stocks experienced an increase in price, with Guangtian Group leading at a rise of 9.94%, followed by Shanzi Gaoke at 6.18% and Baogang Co. at 5.78% [1]. - Conversely, 6 stocks saw a decline, with *ST Sihuan dropping by 5.24%, *ST Jinguang by 4.81%, and *ST Xingguang by 4.79% [1].

Summary of Key Points Core Insights - The report highlights various companies undergoing temporary suspensions of trading due to different reasons, including financial disclosures and potential delisting risks. This indicates a volatile market environment where investor confidence may be affected by such events [2][3][4]. Company Specifics - ST Jiuzhi (000989) announced a temporary suspension of trading on May 6, 2025, due to the cancellation of other risk warnings [2]. - In the case of ST Gongzhi (000584), trading was suspended due to a risk warning regarding potential delisting, effective from April 28, 2025 [2]. - ST Hengli (000622) and Tianmao Group (000627) also faced trading suspensions due to their inability to disclose periodic reports within the legal timeframe, effective from May 6, 2025 [2]. - Binhai Energy (000695) is undergoing a trading suspension as it plans to issue shares for asset acquisition and raise matching funds, effective from April 30, 2025 [2]. - Electric Power Investment Energy (002128) is also suspended for similar reasons related to asset acquisition and related party transactions, effective from May 6, 2025 [2]. Industry Context - The report reflects a broader trend in the market where companies are facing increased scrutiny and regulatory challenges, leading to trading suspensions. This could signal potential investment risks in the affected sectors [2][3][4].

Group 1 - The company operates primarily in the pharmaceutical and health industry, focusing on pharmaceutical manufacturing, retail, research, and investment [3] - The company has approximately 128 drug production licenses, including 55 products listed in the national medical insurance directory [3] - The company has one new drug under research and five unique products or dosage forms nationwide [3] Group 2 - The company received a non-standard audit opinion from Beijing Dehao International Accounting Firm, indicating an inability to express an opinion on the financial report [2] - The company has not distributed cash dividends or bonus shares during the reporting period [2] - The company has initiated bankruptcy reorganization to address historical debt pressures and improve operational sustainability [6][7] Group 3 - The company is at risk of delisting due to its stock price being below 1 yuan for twenty consecutive trading days [8] - The Shenzhen Stock Exchange has issued a notice indicating the intention to terminate the company's stock listing [8]

近日，吉药控股因股价连续20个交易日低于1元，成为2025年第四家触发退市机制的A股药企。从"化工 +医药"双主业光环到六年累亏超40亿，吉药控股的坠落轨迹，映射出医药行业在政策、治理与市场三 重压力下的生存危机。 吉药控股：从跨界神话到退市样本 吉药控股的退市之路堪称"教科书式"风险暴露案例。2014年，公司通过收购金宝药业切入医药赛道， 但"化工+医药"的协同效应始终未能兑现。公司营收从2018年峰值9.4亿元骤降至2024年不足3.6亿元，六 年累计亏损超40亿元。 2022年，原董事长孙军因涉嫌职务侵占被捕，涉案金额达3.3亿元。管理层动荡直接导致融资渠道断 裂，2024年负债率飙升至161.77%，短期债务与可用资金缺口高达21亿元对480万元。伴随业绩连年暴 雷，公司市值从2015年巅峰期的80亿元缩水至退市前不足5亿元，投资者用脚投票最终触发"1元退市"红 线。 2025退市新规显威，医药板块成重灾区 吉药控股并非孤例。2025年退市新规实施后，医药行业已现四例退市/拟退市案例，包括大理药业、龙 津药业、普利制药、吉药控股。医药企业退市潮背后，直指三大结构性矛盾。首先是政策冲击未出清， 带量采购 ...

Group 1 - The average stock price of A-shares is 11.14 yuan, with 70 stocks priced below 2 yuan, the lowest being *ST Jiyao at 0.21 yuan [1] - Among the low-priced stocks, 26 are ST stocks, accounting for 37.14% of the total [1] - The Shanghai Composite Index closed at 3286.65 points as of April 29 [1] Group 2 - In the low-priced stock category, 27 stocks increased in price today, with the highest gainers being Puli Tui, *ST Yangguang, and *ST Jinke, rising by 9.23%, 5.33%, and 4.84% respectively [1] - Conversely, 30 stocks experienced declines, with *ST Zhongcheng, *ST Hengli, and *ST Jiu You showing the largest drops of 17.05%, 5.08%, and 4.95% respectively [1] - The stock price distribution indicates that both high-priced and low-priced stocks constitute a relatively small proportion of the A-share market [1]

Summary of Key Points Core Viewpoints - The report highlights the ongoing trend of stock suspensions due to delisting risk warnings across multiple companies, indicating a potential downturn in market confidence and stability [2][3][4]. Company Listings - Several companies are scheduled for initial public offerings (IPOs) on April 29, 2025, including Tai Li Technology (301595) and Ze Run New Energy (301636), which may attract investor interest [1]. - The report notes the specific dates for various IPO-related activities, such as inquiry periods and fund unfreezing dates, which are crucial for market participants [1]. Stock Suspension Announcements - Numerous companies, including Guohua Network Security (000004) and Nanhua Biology (000504), have announced stock suspensions due to delisting risk warnings, reflecting a significant concern regarding their financial health [2][3]. - The report lists a total of 30 companies facing stock suspensions on April 29, 2025, due to various risk warnings, which may impact investor sentiment and trading volumes [2][3][4]. Special Suspensions - Companies like *ST Xu Lan (000040) and *ST Gong Zhi (000584) are highlighted for potential termination of listings, indicating severe financial distress and regulatory scrutiny [4][5]. - The report emphasizes the importance of monitoring these companies as their situations evolve, which could present both risks and opportunities for investors [4][5].